This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Hoth Therapeutics’s 8K filing here.
About Hoth Therapeutics
Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.
Read More
- Five stocks we like better than Hoth Therapeutics
- How to Buy Cheap Stocks Step by Step
- Why Energy Transfer Stock Could Soar to New Highs in 2025
- What Are Some of the Best Large-Cap Stocks to Buy?
- 3 Buy-and-Hold Stocks for Long-Term Growth
- 3 Healthcare Dividend Stocks to Buy
- Despite Short-Term Risks Freeport McMoran Worth a Look
